Christopher Lathan

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Submitted by shcAdmin on Wed, 12/19/2018 - 15:47
Study ID
DFCI 16-716
Status
Trial Conditions New
Study Information

This study is being conducted by the Alliance for Clinical Trials in Oncology. The Alliance is part of a national research network funded by the National Cancer Institute (NCI). The study will enroll more than 3,000 patients with breast cancer in the United States and Canada. Participants will be randomly assigned (like the flip of a coin) to one of two groups: Weight Loss Intervention Group- Takes part in a telephone-based weight loss program OR Health Education Group- Receives mail or online information about breast cancer topics

Physician
Contact Information

Wendy Loeser RN OCN Clinical Research Dana-Farber Cancer Institute at St. Elizabeth's Medical Center 736 Cambridge St Boston, MA 02135 617-789-3385 Wendy_loeser@DFCI.harvard.edu

Clinical Trial Department
Purpose of Trial
Are you a patient with breast cancer interested in a weight loss program?

If you are, you may be able to help researchers answer an important question: Does losing weight by eating less and exercising lower the risk of cancer recurrence among women who have been diagnosed with early breast cancer? The BWEL Breast Cancer Weight Loss Study aims to answer this question.
Phase
3
Eligibility

You may be eligible to participate if:  You have been diagnosed with stage II-III breast cancer within the last 12 months  You have completed surgery and chemotherapy (if applicable)  You are interested in losing weight and have a body mass index (or BMI) greater than 27 kg/m2  You would like to receive information about health topics  You are willing to be randomly assigned (like a flip of a coin) to one of two groups

Trial conditions

Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for

Submitted by shcAdmin on Wed, 12/19/2018 - 15:47
Study ID
DFCI 16-406
Status
Trial Conditions New
Study Information

Participants will be randomized (like flipping a coin) to one of two arms: Arm 1 - anticoagulation therapy with a low molecular weight heparin (LMWH) alone or followed by warfarin (the usual approach). Arm 2 - anticoagulation therapy with a direct oral anticoagulant (DOAC) (the “study approach”). All of the medications used in this study have already been FDA-approved to treat blood clots. Therapy with a DOAC is already FDA-approved for use as anticoagulation therapy, but DOACs have not been studied extensively in patients with cancer. This study will allow the researchers to gather information about whether anticoagulation therapy with a LMWH alone or followed by warfarin is better, the same, or worse than anticoagulation therapy with a DOAC in patients with cancer.

Physician
Contact Information

Wendy Loeser RN OCN Clinical Research Dana-Farber Cancer Institute at St. Elizabeth's Medical Center 736 Cambridge St Boston, MA 02135 617-789-3385 Wendy_loeser@DFCI.harvard.edu

Clinical Trial Department
Purpose of Trial
Are you a cancer patient who has recently developed a blood clot?

The purpose of this study is to compare two
different approaches to anticoagulation therapy in patients with cancer.
Phase
3
Eligibility

 Your doctor intends you to be on anticoagulation therapy for at least 3 months.  Your blood counts meet the study criteria  You are 21 years of age or older  You are willing to be randomly assigned (like a flip of a coin) to one of two groups You may not be eligible to participate if:  You have acute leukemia  You have ever received or are scheduled to receive a stem cell transplant  You are pregnant or nursing

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Submitted by aschwalb on Thu, 08/10/2017 - 14:39
Study ID
DFCI 16-716
Trial Conditions New
Study Information

This study is being conducted by the Alliance for Clinical Trials in Oncology. The Alliance is part of a national research network funded by the National Cancer Institute (NCI). The study will enroll more than 3,000 patients with breast cancer in the United States and Canada.

Participants will be randomly assigned (like the flip of a coin) to one of two groups:

Weight Loss Intervention Group- Takes part in a telephone-based weight loss program
OR
Health Education Group- Receives mail or online information about breast cancer topics

Physician
Contact Information

Wendy Loeser RN OCN
Clinical Research
Dana-Farber Cancer Institute at
St. Elizabeth's Medical Center
736 Cambridge St
Boston, MA 02135
617-789-3385
Wendy_loeser@DFCI.harvard.edu

Clinical Trial Department
Purpose of Trial
Are you a patient with breast cancer interested in a weight loss program?

If you are, you may be able to help researchers answer an important question: Does losing weight by eating less and exercising lower the risk of cancer recurrence among women who have been diagnosed with early breast cancer? The BWEL Breast Cancer Weight Loss Study aims to answer this question.
Phase
3
Ignore this field in update
Off
Eligibility

You may be eligible to participate if:
 You have been diagnosed with stage II-III breast cancer within the last 12 months
 You have completed surgery and chemotherapy (if applicable)
 You are interested in losing weight and have a body mass index (or BMI) greater than 27 kg/m2

 You would like to receive information about health topics

 You are willing to be randomly assigned (like a flip of a coin) to one of two groups

Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for

Submitted by aschwalb on Thu, 08/10/2017 - 14:17
Study ID
DFCI 16-406
Trial Conditions New
Study Information

Participants will be randomized (like flipping a coin) to one of two arms:

Arm 1 - anticoagulation therapy with a low molecular weight heparin (LMWH)
alone or followed by warfarin (the usual approach).
Arm 2 - anticoagulation therapy with a direct oral anticoagulant (DOAC) (the “study approach”).
All of the medications used in this study have already been FDA-approved to treat blood clots. Therapy with a DOAC is already FDA-approved for use as anticoagulation
therapy, but DOACs have not been studied extensively in patients with cancer.
This study will allow the researchers to gather information about whether
anticoagulation therapy with a LMWH alone or followed by warfarin is better, the
same, or worse than anticoagulation therapy with a DOAC in patients with
cancer.

Contact Information

Wendy Loeser RN OCN
Clinical Research
Dana-Farber Cancer Institute at
St. Elizabeth's Medical Center
736 Cambridge St
Boston, MA 02135
617-789-3385
Wendy_loeser@DFCI.harvard.edu

Clinical Trial Department
Purpose of Trial
Are you a cancer patient who has recently developed a blood clot?

The purpose of this study is to compare two
different approaches to anticoagulation therapy in patients with cancer.
Phase
3
Ignore this field in update
Off
Eligibility

 Your doctor intends you to be on anticoagulation therapy for at least 3 months.
 Your blood counts meet the study criteria

 You are 21 years of age or older

 You are willing to be randomly assigned (like a flip of a coin) to one of two groups

You may not be eligible to participate if:

 You have acute leukemia

 You have ever received or are scheduled to receive a stem cell transplant

 You are pregnant or nursing